Executive Summary

A comprehensive analytical data package is the foundation of a successful Investigational New Drug (IND) submission for any lipid nanoparticle (LNP) therapeutic. Incomplete or ambiguous characterization of particle size, RNA payload integrity, or formulation stability represents a significant risk, often leading to regulatory questions and program delays. This overview outlines the foundational analytical components required to build a robust CMC data package for LNP-based next-generation therapies, ensuring a clear path toward regulatory approval.

Frequently Asked Questions

Q: What are the foundational analytical assays for an LNP formulation IND package?

A robust LNP data package for an IND submission must quantify key physicochemical attributes. This includes dynamic light scattering (DLS) for particle size and polydispersity, zeta potential analysis for surface charge, and cryogenic transmission electron microscopy (cryo-TEM) for morphology. For the RNA payload, assays confirming high encapsulation efficiency and integrity are necessary. Validated potency assays are also required to demonstrate biological function.

Q: How does Franklin Biolabs approach stability studies for novel LNP-RNA therapeutics?

We design and execute phase-appropriate stability programs under GxP conditions that evaluate the LNP therapeutic against predefined specifications over time and under various stress conditions (e.g., temperature, agitation). By tracking defined quality attributes : particle size, RNA integrity, and potency : we generate the data required by regulators to establish appropriate storage conditions and shelf-life, minimizing clinical risk associated with product degradation.

Q: How does Franklin Biolabs leverage data from formulation screening?

We apply analytical frameworks to identify which formulation parameters and material attributes are the strongest predictors of long-term stability and in vivo performance. Instead of relying solely on empirical testing, this data-driven approach de-risks candidate selection and can shorten the path to a lead formulation by focusing development on the most promising candidates.

Building a Defensible CMC Data Package for LNP Therapeutics

The efficacy and safety profile of an LNP-based therapeutic is directly governed by its biophysical and chemical properties. A well-defined analytical control strategy provides the scientific foundation for any program targeting an 18-24 month IND timeline. Our approach focuses on generating a complete dataset that addresses the specific questions regulators will ask regarding product quality, consistency, and stability.

The core of this strategy involves a matrix of orthogonal analytical methods designed to characterize the complete LNP system.

• Particle Size, Polydispersity, and Morphology: We use a combination of DLS and cryo-TEM to confirm that particles are within the target size range for effective biodistribution and cellular uptake, while also ensuring batch-to-batch consistency.
• RNA Payload Encapsulation and Integrity: Ribonuclease protection assays and fluorescence-based methods are used to determine the percentage of the RNA payload successfully encapsulated within the LNP. Capillary electrophoresis or similar techniques confirm the integrity of the RNA, ensuring the full-length construct is present.
• Lipid Component Quantification: The precise molar ratio of ionizable lipids, helper lipids, cholesterol, and PEG-lipids is confirmed using methods such as high-performance liquid chromatography (HPLC) or liquid chromatography–mass spectrometry (LC-MS). Verifying this ratio is fundamental to product consistency.
• In Vitro Potency: Functional, cell-based potency assays are developed to confirm that the LNP can successfully deliver its RNA payload to a target cell and elicit the intended biological response, such as protein expression for an mRNA therapeutic.

Informing Formulation Design with Comprehensive Analytics

An effective analytical strategy moves beyond simple characterization. Our teams analyze multi-parameter datasets from early formulation screens to identify the material attributes and process parameters that correlate with successful outcomes, such as high encapsulation efficiency or superior stability. This intelligence builds a deeper understanding of the formulation design space, allowing for more efficient optimization and selection of a lead candidate with a higher probability of success.

This comprehensive analytical work is performed within our extensive facilities, which include over 100,000 sq ft of specialized laboratory and support space [FBL-VID-06]. The scientific leadership and core operational teams responsible for this work carry a track record that includes a 100% successful IND rate since 2019, established prior to the formal launch of the Franklin Biolabs brand in 2024. This deep expertise in LNP analytics, demonstrated through collaborations with industry leaders like Moderna, provides the foundation for our Vector | CMC | Analytics Services.